Stock & Company Details
Qiagen NV $QGEN
Price:
N/A
N/A
206M
$9.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
23.58
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
QGEN technical indicators
Latest Qiagen NV (QGEN) indicator readings as of 2026-10-09.
QGEN's 14-day RSI is 56.4, in neutral territory. At $45.38 it is trading 6.9% above its 200-day moving average of $42.45, and above its 50-day average of $43.43. Price sits in the middle of its Bollinger Bands ($41.91 to $46.29). ADX reads 12.0, indicating a range-bound market rather than a trend.
QGEN backtested strategy results
How 4 rule-based strategies performed on Qiagen NV (QGEN) over recent history, last backtested 2026-09-08. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +62.2% | 58% | 12 | -22.7% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -10.3% | 42% | 26 | -31.1% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -36.3% | 31% | 32 | -49.5% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -8.9% | 54% | 24 | -26.9% |
Overview
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Finance Bot
Ask your questions
Start by typing a question below.
